{
    "nctId": "NCT00239343",
    "briefTitle": "Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer",
    "officialTitle": "Randomised Placebo-controlled Phase II Trial of Preoperative Therapy With Gefitinib (Iressa\u00ae/ZD1839) and Epirubicin-Cyclophosphamide in Patients With Primary Operable (T2-T3) Oestrogen Receptor Negative Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 160,
    "primaryOutcomeMeasure": "the complete pathological response rate in the two study groups at trial closure",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* histologically confirmed oestrogen receptor negative primary breast cancer, tumour stage T2-3, N0-2, M0. Eligible for surgery, WHO performance score 0-1.\n\nExclusion Criteria:\n\n* any prior anticancer therapy including gefitinib (Iressa\u00ae), epirubicin (Farmorubicin\u2122), or cyclophosphamide, distant metastases or bilateral breast cancer, any evidence of clinically active interstitial lung disease , other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ, pregnancy or breastfeeding",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}